LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target

Photo by nci from unsplash

The plasmablastic lymphomas (PBLs) are a group of aggressive B cell neoplasms that share pathobiological features with large B cell lymphoma (LBCL) and plasma cell myeloma. They are characterized by… Click to show full abstract

The plasmablastic lymphomas (PBLs) are a group of aggressive B cell neoplasms that share pathobiological features with large B cell lymphoma (LBCL) and plasma cell myeloma. They are characterized by a diffuse proliferation of large immunoblastic cells with an immunophenotype resembling plasma cells (Colomo et al, 2004; Swerdlow et al, 2016). First described in the oral cavity of human immunodeficiency virus (HIV)-positive patients, PBL is now recognized to occur in other anatomic sites and in other immunosuppressed states, including among the elderly (Hsi et al, 2011).

Keywords: lymphoma; plasmablastic lymphoma; cd319 cs1; slamf7 cd319; cs1 expressed; expressed plasmablastic

Journal Title: British Journal of Haematology
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.